The research was published in the journal Proceedings of the National Academy of Sciences.

The specialized glycans are capable of binding to laminin and are attached to the α-DG cell surface protein. This binding facilitates adhesion between epithelial and basement membrane cells and prevents cells from migrating. The team of scientists, led by Professor Minoru Fukuda, Ph.D., demonstrated that β3GnT1 controls the synthesis of laminin-binding glycans in concert with the genes LARGE/LARGE2. Down-regulation of β3GnT1 reduces the number of glycans, leading to greater movement by invasive cancer cells. However, when the researchers forced aggressive cancer cells to express β3GnT1, the laminin-binding glycans were restored and tumor formation decreased.

"These results indicate that certain carbohydrates on normal cells and enzymes that synthesize those glycans, such as β3GnT1, function as tumor suppressors," said Dr. Fukuda." Upregulation of β3GnT1 may become a novel way to treat cancer."

Using antibodies, the team investigated the expression of both α-DG and its associated glycans in both normal and cancerous cells. They found that the quantity of α-DG was similar in both cell types, but the level of attached glycans was reduced in the cancer cells. Further study showed that prostate cancer cells that highly expressed the α-DG glycans produced smaller tumors. The team also found that when they knocked down β3GnT1 expression by RNA interference, which reduces protein expression, the amount of glycans decreased even when LARGE was overexpressed.

The scientists demonstrated that β3GnT1 plays a key role in forming laminin-binding glycans attached to α-DG, which in turn reduces cancer cell movement. The study provides a new understanding of the role that complex carbohydrates play in cancer and could lead to new directions in the development of therapeutics.

Source: Burnham Institute (news : web)